Vasopressin casts light on the suprachiasmatic nucleus

Citation for published version:

Digital Object Identifier (DOI):
10.1113/JP274025

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published In:
Journal of Physiology

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Vasopressin casts light on the suprachiasmatic nucleus.

Takahiro Tsuji¹, Andrew J. Allchorne¹, Meng Zhang², Chiharu Tsuji¹, Vicky A. Tobin¹, Rafael Pineda¹, Androniki Raftogianni³, Javier E. Stern², Valery Grinevich³, Gareth Leng¹ and Mike Ludwig¹

¹Centre for Integrative Physiology, University of Edinburgh, Edinburgh, UK,
²Department of Physiology, Augusta University, Augusta GA USA
³Schaller Research Group on Neuropeptides, German Cancer Research Center DKFZ, Central Institute of Mental Health, and University of Heidelberg, Heidelberg, Germany

Correspondence should be addressed to: Mike Ludwig
Centre for Integrative Physiology, University of Edinburgh, Hugh Robson Bldg, George Square, Edinburgh EH8 9XD, UK
Tel: -44 (0) 131 650 3275; Fax: -44 (0) 131 650 2872; email: mike.ludwig@ed.ac.uk

Abstract

In all animals, the transition between night and day engages a host of physiological and behavioural rhythms. These rhythms depend not on the rods and cones of the retina, but on retinal ganglion cells (RGCs) that detect the ambient light level in the environment. These project to the suprachiasmatic nucleus (SCN) of the hypothalamus to entrain circadian rhythms that are generated within the SCN. The neuropeptide vasopressin has an important role in this entrainment. Many SCN neurons express vasopressin, and it has been assumed that the role of vasopressin in the SCN reflects the activity of these cells. Here we show that vasopressin is also expressed in many retinal cells that project to the SCN. Light-evoked vasopressin release contributes to the responses of SCN neurons to light, and enhances expression of the immediate early gene c-fos in the SCN, which is involved in photic entrainment of circadian rhythms.

Key points

- A subpopulation of retinal ganglion cells expresses the neuropeptide vasopressin
- These retinal ganglion cells project predominately to our biological clock, the SCN
- Light-induced vasopressin release enhances the responses of SCN neurons to light.
• It also enhances expression of genes involved in photo-entrainment of biological rhythms

Abbreviations: BSA, bovine serum albumin; CSF, cerebrospinal fluid; DABCO, 1,4-diazabicyclo[2.2.2]octane; DAPI, 4',6-diamidino-2-phenylindole; eGFP, enhanced green fluorescent protein RGCs; retinal ganglion cells; GRP, gastrin-releasing peptide; IGL, intergeniculate leaflet; Opt, olivary pretectal nucleus; PFA, paraformaldehyde; RIA, radioimmunoassay; rAVV, recombinant adeno-associated virus; RHT, retino-hypothalamic tract; SCN, suprachiasmatic nucleus; VP-RGCs, vasopressin-expressing retinal ganglion cells; V1a, vasopressin receptor antagonist (d(CH2)5Tyr(Me)2AVP; vGLUT-2, vesicle glutamate transporter 2; VIP, vasoactive intestinal polypeptide; ZT, Zeitgeber time;

Competing Interests Statement: The authors declare that there are no conflicts of interest.

Funding information: Supported by grants from the Biotechnology and Biological Research Council (BB/J004723/1) and Medical Research Council (MR/M022838/1) (ML, GL), National Institute of Health (RO1HL11225) (JES), Chica and Heinz Schaller Research Foundation (VG), fellowships from the Japanese Society for the Promotion of Science (TT, CT), the Newton International Fellowship program (RP), and a Royal Society of Edinburgh travel grant to VG and ML.

Acknowledgements: We thank R. Landgraf (RIAgnosis, Germany) for measuring vasopressin content in the microdialysates; H. Gainer (Bethesda, USA) for vasopressin antibodies; M. Manning (Toledo, OH, USA) for his vasopressin receptor antagonist; Y. Ueta (Kitakyushu, Japan) for the vasopressin-eGFP and A. Kubasik-Thayil (IMPACT Imaging facility, Edinburgh) for technical assistance with confocal microscopy.

Author Contributions: ML, GL, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article; VG, JES Conception and design, Analysis and interpretation of data; TT, AJA, MZ, CT, VAT, RP, AR, Acquisition of data, Analysis and interpretation of data.
Introduction

The suprachiasmatic nucleus (SCN) of the hypothalamus is the circadian pacemaker of the mammalian brain, orchestrating diurnal cycles in activity, hormone secretion and other physiological variables (Reppert & Weaver, 2002; Hastings et al., 2003; Froy, 2011; Albrecht, 2012) according to an intrinsic circadian rhythmicity of neuronal activity and gene expression. Light entrains the endogenous oscillator in the SCN, synchronizing it with the day-night cycle (Golombek & Rosenstein, 2010), and in mammals information about ambient light intensity originates from a small subset of retinal ganglion cells (RGCs) that are intrinsically photosensitive (Masland, 2001; Hattar et al., 2002; Schmidt et al., 2011), rather than from the rods and cones that are responsible for visual imaging. These intrinsically photosensitive RGCs express the photopigment melanopsin (Lucas, 2013), and use the neurotransmitter glutamate (Marc & Jones, 2002); they project to the SCN to mediate circadian photoentrainment. This neural circuit is independent of conventional retinal phototransduction, since photic entrainment persists in functionally blind transgenic mice lacking rods and cones (Berson et al., 2002).

Changes in day length require progressive adjustments of circadian rhythms, but it would be counter-adaptive to reset a rhythm to any unexpected light signal. Our experience of jet-lag reflects the resistance of our bodily rhythms to abrupt changes (LeGates et al., 2014). Accordingly, in animals, a flash of light close to the end of the night is more likely to result in a phase shift of circadian rhythms than one given earlier. Such light pulses induce expression of a set of immediate-early genes in the SCN, and the ability of light to re-entrain circadian rhythms correlates well with the induction of these genes (Rusak et al., 1993; Kornhauser et al., 1996; Porterfield & Mintz, 2009). Thus a key question is, how can a light pulse trigger gene expression and re-entrain circadian rhythms at some times but not at others? Because the neurones in the SCN display circadian rhythms in gene expression that are maintained even in constant darkness, one possible answer is that these genes regulate intrinsic neuronal excitability, with the consequence that the SCN neurons are only fully responsive to light signals at certain stages of the light-dark cycle. Recent findings indicate that the neuropeptide vasopressin may have a critical role in this process. Transgenic vasopressin V1a receptor knockout mice show damped circadian activity rhythms (Li et al., 2009), and, interestingly, such mice are resistant to ‘jet lag’. In these mice, light pulses immediately re-entrain circadian rhythms (Yamaguchi et al., 2013).

Vasopressin is involved in diverse physiological and behavioural processes; vasopressin secreted from the pituitary gland is essential for fluid and electrolyte balance,
while vasopressin released within the brain has many other roles, including in social behaviour, aggression, and in behavioural rhythms (Bielsky et al., 2005; Ludwig & Leng, 2006; Donaldson & Young, 2008; Mieda et al., 2015). Vasopressin is expressed in the dorsomedial SCN, and is an important output; its secretion into the cerebrospinal fluid (CSF) peaks in the early morning and declines by late afternoon (Kalsbeek et al., 2010). The targets for vasopressin released from the SCN include vasopressin cells in other parts of the hypothalamus, including those in the supraoptic and paraventricular nuclei that regulate diverse physiological processes including water intake (Gizowski et al., 2016) and behaviours (Trudel & Bourque, 2010).

The vasopressin cells in the dorsomedial SCN are not direct recipients of retinal signals; most of the projections from the retina innervate the ventrolateral SCN, which contains other neuropeptides, including vasoactive intestinal peptide and gastrin-releasing peptide (Antle et al., 2009). Here we show that neurons in the ventrolateral SCN are densely innervated by vasopressin-expressing retinal ganglion cells (VP-RGCs), and that more vasopressin is released in response to light at the end of subjective night than at the end of subjective day. Thus neurons in the ventrolateral SCN both control the output of vasopressin from the SCN by their innervation of vasopressin cells in the dorsomedial SCN, and are themselves regulated by vasopressin inputs from the retina.

Material & Methods

Ethical Approval

Procedures conducted in the UK were approved by the local Ethics Committee and the UK Home Office under the Animals Scientific Procedures Act 1986. Experiments in Germany were approved by the Committee on Animal Health and Care of the local governmental body and performed in strict compliance with the EEC recommendations for the care and the use of laboratory animals (86/609/CEE). Experiments in the USA were performed according to institutional guidelines and approval by the Animal Care and Use Committees of the Georgia Regents University.

Animals

Experiments were performed on adult male and female wild-type Sprague-Dawley and transgenic rats (250-350g), housed under controlled conditions (12h light: 12h dark, 21°C) with free access to food and water. Most of the immunohistochemistry was carried out on a homozygous line of transgenic rats expressing a vasopressin-eGFP (enhanced green
fluorescent protein) fusion gene (Ueta et al., 2005).

**PCR**

22-week old female wild-type rats were used to collect supraoptic nucleus and retina tissue. Total RNA was isolated using TRIzol Reagent (Life Technologies, Carlsbad, CA USA). cDNA was synthesised from 1.5μg of total RNA using the Transcriptor High Fidelity cDNA Synthesis Kit (Roche Diagnostics GmbH, Mannheim Germany) according to the manufacturer’s protocol. The PCR was carried out in a 25-μl reaction volume using Go Taq G2 Green Master Mix (Promega Corporation, Madison, WI, USA) and 5, 1, or 0.1μl of cDNA solution were used in each reaction mixture. PCR was performed on a Gene Amp PCR System 9700 (Life Technologies, Carlsbad, CA USA) using the following conditions: 1 cycle of 94°C for 30s followed by 30 cycles of 94°C for 30s, 56°C for 45s and 72°C for 1min, with a final extension step at 72°C for 7min. PCR products are loaded on the 2 % agarose gel and stained with SYBR Safe DNA Gel Stain (Life Technologies, Carlsbad, CA USA). The primer sequences have been published previously (Dijk et al., 2004; Gainer et al., 2011).

**Tissue collection and processing**

Rats were terminally anesthetized and perfusion-fixed with 4% paraformaldehyde (PFA) following a heparinized saline flush, post-fixed and cryoprotected as previously described (Tobin et al., 2010). The eyes were enucleated and placed in 0.1M PB during the heparinized saline flush before transcardial perfusion with PFA. The cornea was cut around the outer edge of the iris to remove the lens and vitreous humour and the eyecups were either placed in 4% PFA solution for 5 min then the retina gently removed and placed back in 4% PFA for 20min or each eyecup was left in 4% PFA solution for 2h. Some retinas were fixed in a solution of 4% PFA + 1% glutaraldehyde but otherwise processed as described above. Tissue was then stored at 4°C in 10% sucrose, then placed in 20% sucrose solution for 120min and finally in 30% sucrose for 12 to 48h, until the tissues had sunk to the bottom of the vials. In eyes which were required for coronal or transverse sections, the tissues were then placed in Tissue-Tek CRYO-OCT (optimal cutting temperature compound) embedding matrix (Fisher Scientific UK)-filled cryo-molds (Sakura Finetek UK Ltd) and gently manipulated to open up and be in the appropriate orientation and then snap-frozen on powdered dry ice. The retinas or eyecups were stored at -20°C until 16-µm sections were cut at -15°C on a cryostat. These sections were thaw-mounted onto SupraFrost slides, allowed to air-dry for 10min before being stored at -20°C until they were processed for fluorescence.
immunocytochemistry. For retinal flat mounts, 3-4 incisions were made from the perimeter of the retina almost to the centre to allow the retina to be gently flattened. The flat-mounts were stored in 0.1M PB until used for immunohistochemistry. After transcardial perfusion, the brains were removed and placed in a 2% PFA and 15% sucrose solution overnight and transferred to 30% sucrose until the tissue had sunk. Coronal 40µm sections were cut using a freezing microtome.

**Immunohistochemistry**

For brain sections and rat retina flat mounts, immunohistochemistry was conducted using a free-floating technique. For retina sections, immunohistochemistry was conducted on the slides either in slide-mailers (Fisher Scientific UK) or after the sections on each slide were outlined with hydrophobic ink (ImmEdge, Vector Laboratories) and thereafter kept horizontal in a light-proofed humid chamber. For each of these techniques, the sections were thoroughly rinsed in 0.1M PB and incubated in 0.1M glycine in 0.1M PB for 30min at room temperature. For immunohistochemistry involving exposure to a biotinylated secondary and fluorescently-tagged streptavidin, sections were blocked for endogenous biotin by incubating them first in 0.01% avidin in 0.1M PB for 30min, washing and then incubating in 0.001% biotin in 0.1M PB for 30min. After washing, sections were incubated for 60min in a blocking buffer consisting of 3-5% normal serum (matched to the host of secondary animal) + 1% bovine serum albumin (BSA) + 0.1% Triton X-100 diluted in 0.1M PB. If the primary antibody was raised in goat, BSA was not used in either the blocking buffer or in the antibody-diluting buffer. The sections were incubated with primary antibodies (Tab. 1) diluted in the blocking buffer. The primary antibodies were applied for 1-5 days at room temperature for first day and thereafter at 4°C. After washing in 0.1M PB, sections were incubated for 60min with secondary antibodies and then washed in 0.1M PB. Sections exposed to biotinylated secondaries were then incubated for 60min with fluorescently-labelled streptavidin conjugate (1:1000). Both secondary antibodies and fluorescently-labelled streptavidin were diluted in 0.1M PB + 0.03% tween. After further washing, sections were incubated in DAPI (4',6-diamidino-2-phenylindole, 1:33000, Life Technologies Ltd, UK) for 5min at room temperature, washed and cover-slipped using either a Mowiol 4-88 (Calbiochem, USA) mounting medium, supplemented with 2.5% DABCO (1,4-diazabicyclo[2.2.2]octane, Sigma) or Prolong Gold (Life Technologies Ltd, UK). No fluorescent labelling was detected when primary antibodies were omitted or when the primary antibodies (Tab. 2) were incubated with a five-fold (w/v) of control immunogen.
before being exposed to the tissue sections (the latter control was conducted whenever a control peptide was available from the supplier of that primary antibody). Most antibody suppliers provided western blot analysis showing the antibody detecting protein in a single band of appropriate size.

**Microscopy**

Fluorescence signals were acquired either using a Nikon AIR confocal or a Zeiss LSM510 Axiovert confocal laser scanning microscope. In either case, the images were acquired at 1024x1024 pixels, using a Nikon Plan Apochromat 1.4 NA x60 oil immersion objective or a Zeiss Plan NeoFLUAR 1.4 NA x63 oil-immersion objective respectively. In all cases, emissions for each fluorophore were obtained consecutively to avoid channel cross-talk. Those images taken throughout each cell at Nyquist sampling rates were deconvolved using Huygens software (Scientific Volume Imaging, Hilversum, Netherlands) and all images were analysed using NIH ImageJ software (v1.48) and figures constructed using Microsoft PowerPoint.

**Cloning of rAAV vectors and virus production**

In addition to tissue from transgenic rats, for morphological studies we used tissue from wild-type rats given bilateral intravitreal injections (under isoflurane anesthesia) of a recombinant adeno-associated virus (rAVV) which caused the expression of Venus or tdTomato under the control of the vasopressin promoter. The conserved promoter region of vasopressin gene, chosen using the software BLAT from UCSC (http://genome.ucsc.edu/cgi-bin/hgBlat) was sub-cloned into a rAAV2 backbone carrying an ampicillin-resistance. It comprises a 1.9kb sequence stretch (revealed by BLAT) that allows for cell-specific expression in hypothalamic vasopressin neurons. Venus or tdTomato was introduced to the plasmid as the gene of interest. Production of chimeric virions (recombinant Adeno-associated virus 1/2; rAAV 1/2) was described previously (Knoblach et al., 2012). Briefly, human embryonic kidney cells 293 (AAV293; Agilent #240073) were calcium phosphate-transfected with the recombinant AAV2 plasmid and a 3-helper system (During et al., 2003). rAAV genomic titers were determined with QuickTiter AAV Quantitation Kit (Cell Biolabs, Inc., San Diego, California, USA) and are ~$10^{13}$ genomic copies per ml.

Rats were anesthetized by medetomidine/ketamine injection and placed in a tiltable stereotaxic frame. A few drops of phenylephrine chlorhydrate and tropicamide (Mydrin-P®) to induce mydriasis, oxybuprocaine chlorhydrate (Benoxil® 0.4%) for additional local
anaesthesia, and ofloxacin (Tarivid® 0.3%) antibiotic was administered into each eye. The head was tilted with its left or right eye uppermost. Intravitreal injections were performed as described by Chiu and colleagues (Chiu et al., 2007). Using a very fine needle (33G, Heraeus, Kulzer Japan Co., Ltd.) attached to a 0.025-ml Hamilton syringe (microliter TM 702), a small puncture was made in the region of the limbus and the needle was lowered into the vitreous using a micromanipulator. 2-5μl of (rAAV) was intravitreally injected into both eyes of transgenic or wild-type rats. The needle was left in position for 30-60s and then withdrawn slowly. The procedure was repeated on the other side of the same eye before being repeated on the other eye. Injections were performed under a dissecting microscope to ensure correct positioning of the needle and to monitor loss of fluid from the eye. Intravitreal injections were performed by a trained ophthalmologist. Virally-transfected rats were left for two weeks before transcardial perfusion.

Retrograde Tracing

In 12 eGFP rats under isoflurane anesthesia, 50-100nl of the retrograde tracer (Red-Retrobeads, Lumafluor Inc, Florida, USA, or Fluorogold Sigma) was microinjected stereotaxically in the left SCN (bregma -1.1, lateral +0.3, depth 8.6mm from dura), IGL (bregma -4.5, lateral +4.0, depth 5.5mm from dura), OPt (bregma -4.7, lateral 1.3, depth 4.4mm from dura) or bilaterally into the left and right superior colliculus (bregma -5.3mm, lateral 1.5mm, depth 4.8mm from dura) (Paxinos & Watson, 2006) over 20 min. One week later, rats were perfused transcardially with 4% PFA and brains and retinas were processed for immunohistochemistry.

Fos expression

The effects of light on Fos expression on eGFP-positive RGCs and the SCN was evaluated in eGFP rats fixed by transcardial perfusion during the day (noon) or night after light exposure (1000 lux, for 1h, 2h before the end of the night). Standard immunocytochemistry was performed on floating retinal flat mounts or SCN sections using a polyclonal antibody raised in rabbit against the N-terminal amino acids 4-17 of the protein product of human c-fos (PC38, Millipore, UK). For double immunocytochemistry, a polyclonal antibody raised in chicken against eGFP (Abcam UK) was used. Antibody-antigen complexes were visualized by using ABC methods with a Vector stain elite kit (Vector Laboratories, Bucks, UK) intensified with nickel-intensified diaminobenzidine (Ni-DAB; single immunocytochemistry) or with DAB only (double immunocytochemistry). Fos-
positive nuclei and the percentage of activated cells were counted in the SCN at the level of maximal cross-sectional area by an observer blind to the treatment group.

**Intracerebroventricular infusion of vasopressin V1a antagonist**

Wild-type rats were implanted with a left lateral ventricular brain infusion cannula (Alzet BIK2, Charles River Ltd, Margate, Kent, UK) under isoflurane anaesthesia via a burr hole in the skull drilled 0.6mm posterior to and 1.6mm lateral to bregma (Paxinos & Watson, 2006). The cannula was secured in place using dental cement glued to two stainless steel screws driven into the skull and then connected via polythene tubing to a subcutaneous osmotic minipump (Alzet 2001). The pumps were prepared as in instructions and filled with a vasopressin V1a receptor antagonist (d(CH$_2$)$_5$Tyr(Me)$_2$AVP, Dr. Manning (Kruszynski et al., 1980)) or aCSF and set to deliver at a rate of 416 ng h$^{-1}$, for 3 days (n=5-7/group). This antagonist binds similarly to V1a and V1b receptors, and the dose is about twice that used previously (Subburaju & Aguilera, 2007), who delivered 230 ng h$^{-1}$ for 28 days and showed effectiveness at blocking the effects of exogenous vasopressin. Rats were housed singly and, on the day of experiment, rats were moved into a brightly lit laboratory (1000 lux) and placed into empty clear cages for 1h. They were then terminally anesthetised for tissue fixation (see above).

**In vivo electrophysiology**

Urethane-anesthetised adult male wild-type rats (ethyl carbamate 1.25g kg$^{-1}$, i.p.) were tracheotomized and the area below the SCN was exposed using a transpharyngeal approach (Ludwig et al., 2002; Saeb-Parsy & Dyball, 2003). An injection cannula was placed into the third ventricle (coordinates: 0.6 mm caudal to bregma, 1.5 mm lateral to midline, 5 mm deep) (Paxinos & Watson, 2006) for icv drug administration, and in some experiments a bipolar stimulating electrode was placed onto the exposed optic nerve, as above, contralateral to the recording side. Recordings were made from single cells in the SCN using a glass microelectrode (tip diameter ~1μm) filled with 0.9% NaCl; firing rates were recorded using Spike2 software and CED 1401 interface (Cambridge Electronic Design, Cambridge, UK) on a PC. The spontaneous activity of each SCN neuron was recorded for at least 5min before treatment. Trains of stimuli (matched biphasic pulses; 1-ms pulses, 1mA peak-to-peak; 50Hz for 0.5s, every 1min) were applied to the contralateral optic nerve. Light was applied at 100lux or 1500lux for 5s at 1-min intervals after the rats were held in dark conditions with
eyes covered with aluminum foil. Electrical or light stimulation was repeated before, during and after injection of a vasopressin antagonist into the 3rd ventricle, 2-3mm caudal to the recording site. The injection cannula was backfilled with vasopressin V1a antagonist (40ng in 2µl aCSF)(Tobin et al., 2010) followed by 2µl of aCSF to prevent diffusion of antagonist into the SCN; in tests, the first injection of 2µl was thus of aCSF, followed 10min later with an injection of antagonist. Responses to light were averaged over 10-20 presentations; responses to antagonist began ~ 5min after injection so the average of responses after this time was taken. Only one cell was tested in each experiment. One of the cells tested with the antagonist was not tested with aCSF; in that experiment a different cell had been tested with aCSF with no response (not shown) but was lost before the antagonist could be injected.

**In vitro electrophysiology**

eGFP rats were terminally anesthetized with pentobarbital (50mg kg\(^{-1}\)) and retinas dissected out as described previously (Schmidt & Kofuji, 2011). Retinas were treated with enzymes by adding collagenase and hyaluronidase (Worthington Chemicals) to Ames' solution for 10min in a 95% O\(_2\)/5% CO\(_2\) environment, shaken gently before being washed 3 times in carbon-saturated Ames' solution and stored in dark for at least 1h before been moved to the recording chamber. Retina flat mounts were superfused with Ames’ solution (30°C–32°C) at 3ml min\(^{-1}\). Conventional whole-cell patch-clamp recordings, using a K\(^+\)-gluconate-based internal solution, were obtained as previously described (Son et al., 2013). Some neurons were intracellularly labeled with Alexa Fluor 555 (100μM) or biocytin (1%). Recordings were obtained from eGFP-labeled VP-RGCs neurons. For bath-applied drugs, mean firing activity and membrane potential values were calculated from a 2-min period before drug application and in a 2-min period around the peak effect.

**Microdialysis**

In wild-type rats, the brain region above the SCN was exposed by the transpharyngeal approach under urethane anaesthesia (ethyl carbamate 1.25g kg\(^{-1}\), i.p.) as previously described (Ludwig et al., 2002). An in-house designed U-shaped microdialysis probe (molecular weight cut-off of 6kDa, Fleaker\(^{®}\) hollow fibre, Spectrum Medical Inc., Los Angeles, CA, USA) was positioned into the left SCN after opening of the meninges. After implantation, there was an equilibration period of at least 1h before six consecutive 30-min dialysis samples were collected. The samples were frozen and stored at −20°C until assay for vasopressin. After two 30-min baseline periods, a stimulating electrode (Clarke...
Electromedical, SNEX-200X) placed onto the optic nerve closely behind the right eye was set to deliver trains of matched biphasic pulses (0.1ms, 1mA peak-to-peak; 50Hz for 5s, every 1min for 30min). In other experiments, light was applied (1min on/1min off for 30min) to the eye contralateral to the recording site using a portable surgical light (1500lux) at early morning or late evening during then third sampling period. For the early morning measurements, rats were anesthetised at ZT0, and kept in the dark (covering the eyes with aluminum foil) before stimulating with light at ZT4. For the late evening measurements, rats were anaesthetised at ZT9 and then kept in the dark (covering the eyes with aluminum foil) before stimulating with light at ZT12. The SCN was dialysed with aCSF (pH 7.2, composition in mM: NaCl 138, KCl 3.36, NaHCO₃ 9.52, Na₂HPO₄ 0.49, urea 2.16, CaCl₂ 1.26, MgCl₂ 1.18) at 3μl min⁻¹). At the end of each experiment, during sample period six, a modified aCSF containing 150mM KCl plus 100μM veratridine was retrodialysed into the SCN to trigger vasopressin release as a control for probe placement, and only data from experiments in which this evoked at least a 3-fold increase in vasopressin concentration were analysed. Brains were removed and cut for histological confirmation of microdialysis probe placement.

Vasopressin in microdialysates was measured after lyophilization as previously described (Landgraf et al., 1995; Paiva et al., 2016) by a sensitive and selective radioimmunoassay (RIA; detection limit: 0.1pg sample⁻¹; cross-reactivity less than 0.7%, RIAgnosis, Sinzing, Germany). Samples for measurement were blind coded.

Statistics

Fos expression in the retina. Three groups were compared by the non-parametric Kruskall-Wallis test, followed by Mann-Whitney U tests to test the hypotheses a) that light activates Fos expression in VP-RGCs and b) that expression is higher in the light than in the dark period.

Retinal vasopressin content. Two groups (n=7) were compared to test the hypothesis that the vasopressin content of the retina differs between dark and night. Values were compared by a two-tailed t-test.

Fos expression in the SCN. First, we compared light-induced Fos expression in early vs late night. In subsequent experiments we tested the hypothesis that a V1a antagonist would attenuate light-induced Fos expression in the late night. Fos-positive nuclei were counted in each SCN in 3-5 sections per rat, and the median calculated; to combine these for group values, the medians were log-transformed as their distributions were skewed; n values are
animal means. Groups were compared with a one-tailed t-test, as this experiment tested a predetermined unidirectional hypothesis.

**Microdialysis.** In the experiment shown in Fig. 6, the basal levels of vasopressin varied in a 3-fold range between experiments, and so all data were normalized to the concentration in the first basal sample. The normalized data (excluding the first basal sample) from the two groups were compared by a repeated measures ANOVA followed by pairwise tests, using Bonferroni’s and Tukey’s multiple comparisons test.

**In vivo electrophysiology.** Two hypotheses were tested in separate experiments: that V1a antagonist attenuates SCN responses to light, and that it attenuates SCN responses to electrical stimulation of the optic nerve. Each of these was tested by a paired comparison of the (mean) response in control condition and the mean response after application of the antagonist, using a two-tailed Wilcoxon signed rank test.

---

**Results**

**Characterisation of VP-RGCs**

Vasopressin content in the retina has been previously described, and vasopressin has been found (by immunocytochemistry) to be expressed in some cells in both the ganglion cell layer and the inner nuclear layer of the retina (Gauquelin et al., 1983; Djeridane, 1994; Moritoh et al., 2011). We studied these cells in a transgenic rat strain in which eGFP (enhanced green fluorescent protein) is expressed under the control of the vasopressin promotor (Fig. 1A,B) (Ueta et al., 2005). eGFP-expressing cells comprised about 1% of cells in the ganglion cell layer (1.07±0.01% of 33868 cells from 9 retinas), and were sparsely distributed across the whole retina. By immunocytochemistry, we established that all the eGFP-expressing cells that we examined in the retina also expressed vasopressin-associated neurophysin: this large peptide is part of the vasopressin precursor peptide (Fig. 1C). eGFP (and vasopressin neurophysin) was also expressed in some small cells in the inner nuclear layer, which contains interneurons that do not project out of the retina.

The VP-RGCs were heterogeneous in size. In the inner nuclear layer, most e-GFP expressing cells were small: a sample of 21 of these cells had a mean (S.E.M.) cross-sectional area of 58±2.6µm² (range 48-85 µm²). By contrast, in a sample of 43 eGFP-expressing cells in the ganglion cell layer, 25 small cells had a mean (S.E.M.) cross-sectional area of 83±2.7µm² (range 62-99µm²), while the ten largest cells had a mean (S.E.M.) cross-sectional area of 291±13.2µm² (range 154-333µm²). Using triple immunohistochemistry, we found...
that many large (but not small) VP-RGCs co-expressed the vesicle glutamate transporter 2 (vGLUT-2), indicating that these cells use glutamate as a neurotransmitter (Fig. 1E) (Fujiyama et al., 2003). In mammals, melanopsin is found in intrinsically photosensitive RGCs that project to the SCN and plays a critical role in regulating circadian rhythms (Provencio et al., 2000; Hattar et al., 2002; Hankins et al., 2008). VP-RGCs were often closely juxtaposed to immunoreactive melanopsin cells (Fig. 1F). Of the small VP-RGCs, only one cell of 300 counted contained detectable immunoreactive melanopsin, but, of the large VP-RGCs, 25% (21/80) co-expressed melanopsin. We found no co-localisation of eGFP with calretinin, parvalbumin, tyrosine hydroxylase, glycine, choline acetyltransferase or GAD65/67 (Fig. 2A-F), which label known subpopulations of retinal interneurons (Marc & Jones, 2002).

The vasopressin-eGFP transgene encodes a modified vasopressin precursor with eGFP fused in-frame at the C terminus (Ueta et al., 2005 and D. Murphy, personal communication). The signal peptide, vasopressin and neurophysin portions of the precursor are intact, and may be expressed from the transgene, thus the vasopressin-associated neurophysin in eGFP rats may reflect either endogenous expression or transgene-driven expression. We therefore confirmed the expression of vasopressin in retinal cells in wild-type rats using antibodies against vasopressin-neurophysin (see below), the presence of vasopressin mRNA in the retina by PCR (Fig. 1D, 3B), and the production of vasopressin by radioimmunoassay. The vasopressin content of the retina in wild-type rats was higher in the late afternoon (ZT11) than in the early morning (ZT1; 25±2.6 vs. 52±8pg per retina, n=7 per group, P<0.015), consistent with light-induced activation of synthesis.

Venus labelling

To visualise the axons of the VP-RGCs in wild-type rats, we made intravitreal injections of a recombinant adeno-associated virus (rAAV) that results in the expression of a fluorescent protein Venus (Figs. 3A,B; supplementary animation) or tdTomato under the control of 1.9 kbp of the vasopressin promoter (Fig. 4). We confirmed the successful transfection of retinal vasopressin cells by immunohistochemistry (Fig. 3B) for vasopressin neurophysin. This confirms that the large RCGs do indeed express the endogenous vasopressin gene, as the AAV vector does not contain vasopressin coding sequences.

Unlike the eGFP-vasopressin transgenic rats, where the eGFP is packaged inside the same vesicles as vasopressin (Ueta et al., 2005), these fluorescent proteins are released into (and fill) the cytoplasm of the neurons allowing tracking of thin neurites (Knobloch et al.,
In the transfected retinas, we found Venus labelling in the ganglion cell layer but not in the inner nuclear layer (Fig. 3C,D). Only larger VP-RGCs expressed Venus; no Venus was found in the small cells in either the inner nuclear layer or the ganglion cell layer. In three retinas we sampled 220 Venus-labelled cells and 113 melanopsin-labelled cells; 45% of the Venus-labelled cells contained immunoreactive melanopsin and 88% of the melanopsin cells contained Venus, suggesting that most melanopsin-containing cells express vasopressin. We traced the passage of Venus-labelled axons into the optic nerve (Fig. 3E), and found a dense plexus in the ventrolateral SCN (Fig. 3F). Using triple immunohistochemistry for Venus, vGLUT-2 and vasoactive intestinal polypeptide (VIP) or gastrin-releasing peptide (GRP) we found that 74% of VIP cells and 66% of GRP cells were apposed by boutons from Venus-labelled fibres (Fig. 3I,J). The Venus-labelled fibres co-expressed vGLUT-2 indicating that they were glutamatergic; as expected, vGLUT-2 was not co-expressed with either VIP or GRP, which are both known to use GABA as a conventional neurotransmitter.

We also found Venus-labelled fibres in the intergeniculate leaflet (IGL), which is involved in regulation of circadian rhythms via its projections to the SCN (Hattar et al., 2006), and in the olivary pretectal nucleus (OPt), which controls the pupillary light reflex (Gamlin, 2006). However, we found no Venus-labelled fibres entering the superior colliculus, which is a major projection area of classical image-forming RGCs (Feinberg & Meister, 2015) (Fig. 4), some were found on the outskirts of the superior colliculus, but none were seen to enter this region. In two animals we transfected the right eye with AAV expressing Venus and the left eye with an AAV expressing tdTomato, both under the control of the vasopressin promoter. The labeled fibers terminated in the SCN, IGL and OPt (Fig. 4); most fibers were found at sites contralateral to the injected eye, but there was a substantial ipsilateral projection to the SCN in particular.

Retrograde tracing

We confirmed these projections by retrograde tracing studies (Fig. 3G,H). When retrograde tracer beads were injected into the SCN, IGL or OPt (n=2-4 per area) we found labelling of large (but not small) eGFP-positive cells in the ganglion cell layer, and no labelling of any cells in the inner nuclear layer. We found no labelling after injections into the superior colliculus (Fig. 3H). To estimate how many of the RGCs that project to the SCN express vasopressin, we injected fluorogold into the SCN to fill this region completely (Fig. 3G). For the injection which achieved the best fill, we studied seven retinal sections with
confocal microscopy. Of 176 melanopsin-labelled cells, 142 were retrogradely labelled with fluorogold; of these, 41 also expressed eGFP. In the same sections, we found only 8 VP-RGCs that were labeled with fluorogold but which appeared to contain no melanopsin. These experiments confirmed that most of the retinal cells that project to the SCN contain immunoreactive melanopsin, and that vasopressin is expressed in a substantial subset of these cells and also in some cells that project to the SCN which did not apparently contain detectable amounts of immunoreactive melanopsin.

Light responsiveness of RGCs

To determine the response of VP-RGCs to light we measured the expression of the immediate early gene c-fos in the retina by immunocytochemical detection of Fos, the protein product of c-fos. In response to 1-h light stimulation of dark-adapted retinas (ZT21), there was a significant increase in Fos expression in VP-RGCs (8.1±1.0% of VP-RGC’s expressed Fos after light exposure vs. 0.2±0.2% with no light exposure, n=3 and n=6 respectively, p=0.0019, Fig. 5A,B). Fos expression in VP-RGCs was even higher in retinas taken at ZT6 (13.8±3.8%, n=6), suggesting sustained expression of Fos in VP-RGCs throughout the day.

To characterise the responsiveness of VP-RGCs to light, we made in vitro patch-clamp recordings from 88 large RGCs identified by their expression of e-GFP; 58 of these cells were transiently excited by light, and the other 30 were inhibited (Fig. 5C,D); previously, all immunoreactive melanopsin RGCs have been reported to be excited by light (Schmidt et al., 2011). Current-clamp and voltage-clamp recordings from the light-activated VP-RGCs showed that afferent synaptic activity was increased during light stimulation, suggesting that activation was mediated at least partially by synaptic input (Fig. 5F). The close juxtaposition of the VP-RGCs to melanopsin cells indicates that they may receive these excitatory synaptic inputs from neighboring, intrinsically photosensitive melanopsin cells (Schmidt et al., 2011; Hughes et al., 2016).

Vasopressin actions in the SCN

We then recorded the spike activity of single SCN neurons in urethane-anesthetised rats (Tsuji et al., 2016). About two thirds of light-responsive cells (150/222) were excited by light (5-s pulses) and about one third were inhibited. In ten cells excited by light (each from a different rat), responses were measured before and after injection of aCSF and after injection of a vasopressin V1a receptor antagonist into the third ventricle. The light-induced activation was unaffected by aCSF injection but was reduced by 30±8% after antagonist injection.
We also tested the responses of SCN neurons to electrical stimulation of the retino-hypothalamic tract (RHT; 5-s trains at 50Hz) (Fig. 6A-E). Seven SCN neurons (from seven rats) showed a prolonged excitatory response (for 3-7s after stimulation) that was attenuated by icv injection of the V1a antagonist (Fig. 6E).

A short light pulse, given during the subjective night, induces Fos expression in the SCN, and this correlates with the ability of light to phase-shift activity-rest cycles (Fig. 7) (Ding et al., 1994). Consistent with previous studies, 60-min of light exposure at Z21 induced robust Fos expression in the SCN, and this activation was significantly greater than that induced by the same light exposure given at ZT15 (Fig. 7B). In separate experiments, rats were chronically infused icv with the V1a antagonist or vehicle via a sub-cutaneously implanted osmotic minipump connected to a cannula implanted in the lateral cerebral ventricle. Light-induced Fos expression at Z21 was significantly less in rats infused with the V1a antagonist (Fig. 7A,C) than in vehicle-infused rats.

Finally, we measured vasopressin release in the SCN (by microdialysis in urethane-anaesthetised rats) in response to light exposure. In pilot experiments we found that application of light (1 min on, 1 min off for 40 min) to the contralateral eye at ZT6 increased vasopressin release in the SCN from 0.54±0.14 to 1.76±0.35 pg sample$^{-1}$ in samples collected every 40 min (n=6 per group, p<0.05). In two further groups of rats, we collected 30-min samples at the beginning and end of subjective day in before and after light was given for 30 min. The ‘early morning’ group was exposed to light at ZT3 after being maintained in the dark continuously after the preceding dark phase; the ‘evening’ group was exposed to light at ZT12 after being maintained in the dark from ZT9, to ensure dark adaptation of light responsiveness. In the ‘early morning’ group, light exposure was followed by a significant increase in vasopressin concentration, whereas in the ‘late evening’ group, light exposure produced a significant decrease (Fig. 7D).

**Discussion**

The present study shows that vasopressin, well known to be an important output of the SCN (Kalsbeek et al., 2010), is also a time-dependent mediator of light information from the retina to the SCN, and so is likely to contribute to the effects of vasopressin on jet-lag (Yamaguchi et al., 2013). The expression of neuropeptides in this projection has clear functional significance. These cells use glutamate as a neurotransmitter, secreted from small synaptic vesicles. Because glutamate can be rapidly recycled, this signalling is constantly
available. However, many of the RGCs that project to the SCN also contain the neuropeptide PACAP (Hattar et al., 2002; Schmidt et al., 2011), or as described here, vasopressin. At present, we do not know whether vasopressin and PACAP are co-expressed or are in separate populations of RGCs. Neuropeptides are not contained in the same vesicles as glutamate, but are packaged in separate, large vesicles that are synthesised at the cell body and transported along the axons (Burbach et al., 2001): these vesicles cannot be recycled as small synaptic vesicles are. Light stimulation rapidly induces Fos expression in VP-RGCs, and induction of Fos expression is implicated in the regulation of neuronal vasopressin synthesis (Cunningham et al., 2004). Thus, it is likely that, in VP-RGCs, Fos expression is linked to up-regulation of peptide synthesis to replenish what has been released from the terminals. However, the path length from retina to SCN in the rat is >20mm, and (in magnocellular vasopressin neurons) vasopressin-containing vesicles are transported along axons at only ~140mm/day (Burbach et al., 2001). Given this, and given the delays between stimulation and production of new vesicles, the depletion of peptide by light-induced activation of release in the SCN cannot be replenished without a lag time of several hours. Thus, at the terminals in the SCN, the availability of peptide for release must be subject to a diurnal cycle of depletion and replenishment.

We have shown here that light given at the end of the dark phase consistently evokes measurable vasopressin release in the SCN, whereas light given at the beginning of the dark phase does not. We predicted that light stimulation would increase vasopressin release from retinal afferents, and would excite a majority of the first order recipient neurons in the SCN. The retinal afferents do innervate predominantly VIP and GRP neurons, but not directly innervate the intrinsic vasopressin cells of the SCN, which are regulated by inhibitory GABAergic projections by the retinal recipient neurons. However, some of the retinal recipient neurons are inhibited by light, so there may be activation of intrinsic vasopressin cells from these inputs. In addition, it has been suggested that GABA may excite some SCN vasopressin neurons (Belenky et al., 2010). Thus, how much of the vasopressin collected in the microdialysates is released from the retina projection or released from the endogenous population of SCN vasopressin neurons in response to light stimulation is unclear. SCN vasopressin neurons project to the paraventricular nucleus of the hypothalamus, the subparaventricular zone, medial preoptic area, and into the contralateral SCN. SCN vasopressin neurons have also axon collaterals which remain inside the boundaries of the SCN (Pennartz et al., 1998) and release vasopressin from their somata and dendrites (Castel et al., 1996).
We have also shown that light-induced Fos expression in the SCN is higher at the end of the night than earlier, and SCN Fos expression has been linked to light-induced phase shifts. Accordingly, cyclical availability of neuropeptides for release may explain why a light pulse given close to the end of the night is more likely to result in a phase advance of circadian rhythms than one given earlier.

Exactly why light is so ineffective at eliciting Fos expression in the early part of the dark phase remains intriguing; even if the retinal terminals are depleted of vasopressin they should still be releasing glutamate in response to light. The answer may simply be that, although c-fos is often thought of as an indiscriminate marker of neuronal excitation, this is over-simplistic: in magnocellular oxytocin neurons for example, the neuropeptide a-MSH induces Fos expression but inhibits neuronal activity (Sabatier et al., 2003), while antidromic stimulation of increased spike activity is completely ineffective at increasing Fos expression (Luckman et al., 1994). The likely mechanistic link between synaptic activation appears to be via increased intracellular calcium, and as vasopressin is a potent mobiliser of intracellular calcium stores (Sabatier et al., 1998), it may be a particularly potent inducer of Fos expression.

Vasopressin is involved in diverse physiological and behavioural processes; vasopressin secreted from the pituitary gland is essential for fluid and electrolyte balance, but vasopressin released within the brain has many roles, including in social behaviour, aggression, and in behavioural rhythms. Vasopressin is an important output of the SCN; its secretion into the CSF peaks in the early morning and declines by late afternoon (Kalsbeek et al., 2010), and its targets include vasopressin cells in other parts of the hypothalamus. In particular, vasopressin released from the SCN during late sleep activates osmosensory afferents to the vasopressin neurons in the supraoptic nucleus (Trudel & Bourque, 2010) and to neurons in the organum vasculosum of the lamina terminalis (Gizowski et al., 2016). Supraoptic neurons secrete vasopressin from nerve terminals in the posterior pituitary which acts on the kidneys to concentrate the urine. Regulation of this antidiuretic system by the SCN suppresses nocturnal enuresis, and is important in maintaining sleep. Magnocellular vasopressin neurones of the supraoptic nucleus also directly control a diversity of behavioural processes, via central axonal projections and via extensive dendritic secretion of vasopressin (Ludwig & Leng, 2006; Neumann & Landgraf, 2012; Stoop, 2012). Thus although vasopressin is expressed at several sites in the nervous system as well as in the retina, it appears that some of these vasopressin neurons are linked in functionally coherent chains to integrate multiple physiological and behavioural functions.
Shift work that includes a night-time rotation and long distance travel has become an inevitable attribute of today's 24-h society. The related disruption of the human circadian time organization leads in the short-term to an array of jet-lag-like symptoms, and in the long-run it contributes to weight gain and obesity, metabolic syndrome, type II diabetes, and cardiovascular disease. Studies suggest increased cancer risk, symptoms of insomnia, depression, elevated cortisol levels, cognitive impairment, and premature mortality (Hastings et al., 2003; Froy, 2011; Kondratova & Kondratov, 2012). The mechanisms leading to circadian dysfunction are largely unknown. The reported association of vasopressin with jet-lag (Yamaguchi et al., 2013) raises the interesting possibility that interventions in vasopressin signalling from the retina may have important therapeutic benefits.

**Figure Legends**

**Figure 1: Vasopressin neurons in the retina.**

A, Flat mount of retina, focused on the ganglion cell layer (GCL), shows dispersed eGFP-expressing cells (green cells); the blue staining is a nuclear marker DAPI, to show the location of all cells in the field of view; the inset shows the location of the image within the flat mount. B, eGFP-cells occur in both the ganglion cell layer (GCL) and the inner nuclear layer (INL), as shown in a cross section of the flat mount. C, eGFP-cells express vasopressin-neurophysin (VP-NP); the successive images show fluorescence for eGFP, immunoreactive VP-NP, and overlaid images. D, PCR confirmation of expression of vasopressin mRNA (VP, 77bp) and actin mRNA in the supraoptic nucleus (positive control) and the retina of wild type rats; the supraoptic nucleus contains magnocellular neurons that project to the posterior pituitary gland. Note there is no detectable oxytocin mRNA (OXT, 62bp) in the retina; oxytocin is a closely related peptide that is also expressed in the supraoptic nucleus. E, eGFP-cells (shown in a flat mount) co-express the vesicle glutamate transporter vGLUT-2 (white arrows) indicating that they use glutamate as a conventional neurotransmitter. F, Some eGFP-cells co-express the photopigment melanopsin (white arrows, yellow arrow shows a cell immunopositive for melanopsin only).

**Figure 2: Vasopressin neurons in the retina.**

Immunohistochemistry for retinal cell types Fluorescence immunohistochemistry showing that eGFP-expressing RGCs (green in top layer) and amacrine cells (green lower layer) do not co-express markers commonly used to identify retinal cells (red), including calcium binding proteins (A-C), neuropeptides (D-F), and “classical” transmitters (G-J).
Figure 3: VP-RGC transfection and projections.

A, Scheme of the viral vector used to infect VP-RGCs. B, Intravitreal injection in wild type rats of a rAAV-expressing Venus (green) under the control of the vasopressin promoter infects RGCs that express vasopressin neurophysin (VP-NP, red; yellow in overlay). C, Venus labelling in a retinal flat mount. D, Dendrites of RGCs branching into the inner nuclear layer (INL) (D) or ganglion cell layer (GCL) (Di). E, Venus-labelled axonal projections converge on the optic disc, where the optic nerve leaves the retina. F, enlarged in Fi, The VP-RGCs project (green fibres; Venus) to the ventrolateral SCN; intrinsic vasopressin cells in red. G,H, Retrograde tracer is found in some VP-RGCs (Gi,Hi) after microinjection into the SCN (G) (fluorogold), but not after injection into the superior colliculus (H, Fluoro-Red beads). I,J, Terminal boutons of Venus-labelled fibres in the SCN express vGLUT-2 and target (I) vasoactive intestinal polypeptide (VIP) and (J) gastrin-releasing peptide (GRP) cells. The blue staining is a nuclear marker DAPI. 3V 3rd ventricle, OC optic chiasm; ITR inverted terminal repeat sequence.

Figure 4: Projections of VP-RGCs

DAB immunohistochemistry in wild type rats after intravitreal injection of a rAAV-expressing Venus under the control of the vasopressin promoter into the retina shows some fibers projecting to the (A) integeniculate leaflet and (B) olivary pretectal nucleus, but not to the (C) superior colliculus. D, Scheme of the viral vectors used to infect VP-RGCs. Intravitreal injection of a rAAV-expressing Venus (green) into (E) the right retina and tdTomato (red) into (F) the left retina shows (G-K) that the fibers terminate in the SCN, integeniculate leaflet (IGL) and olivary pretectal nucleus (OPt) with the majority contralateral to the injected eye.

Figure 5: Light exposure excites VP-RGCs.

A, The expression of Fos in VP-RGCs in the day (ZT6). B, Expression is higher in the day (ZT6) than in the dark (ZT21) and is induced by light stimulation in the dark (mean difference 7.5, 95% CI 4.0 to 11.0, **P=0.0019). Patch-clamp recordings of VP-RGCs showing examples of (C) a transient increase in spike activity during light exposure, and (D) inhibition of spike activity. E, Example of a patch-clamp recorded eGFP-labeled RGC filled with biocytin (red; overlay with green gives the yellow signal in the soma). F, Spikes in response to light are initiated by excitatory postsynaptic potentials (arrow). G, Summary of electrophysiology data showing changes in voltage potential (Vm, for stimulated (mean difference 16.2, 95% CI 12.8 to 19.6, ***P=0.0001) and inhibited neurons (mean difference -6.56, 95% CI -7.9 to -5.2, ***P=0.0001), n=58 excited cells, 30 inhibited cells, means + S.E.M; *** P<0.001).

Figure 5B source data; Figure 5G source data
Figure 6: Vasopressin effects on SCN cells.

A,B, icv injection of a vasopressin V1a antagonist blocks the response of an SCN neuron in vivo to electrical stimulation of the RHT (grey bar), shown in post-stimulus time histograms before (A) and after (B) antagonist injection. C, Example of the response of a SCN cell to repeated electrical stimulation of the RHT; the black symbols plot the number of spikes recorded in the 6s after stimulation of the RHT for 0.5s at 50Hz delivered every minute; the open symbols plot the number of spikes in the following 6s. A V1a antagonist given icv (arrow) markedly attenuates the response to stimulation for about 20 min after a lag of 3 min. D, Mean (S.E.M.) response to RHT stimulation of the same cell, shown in blue for the first ten responses plotted in C and in red for the ten responses plotted between 20 and 30 min in C. E, Mean responses to RHT stimulation of 7 SCN cells plotted as % differences to control firing rate after icv injection of aCSF followed by icv injection of the V1a antagonist and after recovery (washout) (**P=0.009 vs. control; two-tailed Wilcoxon signed rank test; numbers in columns are n/group). F, Icv injection of antagonist attenuates the responses of SCN neuron in vivo to light: this panel shows the response of a representative SCN neuron to light; it shows the mean (S.E.M.) responses to repeated light exposures before and after injection of the antagonist (n=9 in each case).

Figure 6E source data.xlsx; Figure 6F source data.xlsx

Figure 7: Vasopressin effects on SCN Fos expression.

A, Hypothalamic sections at the level of the SCN stained for Fos (black nuclear stain), and lightly counterstained with nuclear fast red. A 60-min light pulse presented at the beginning of the dark period (ZT15) induces more Fos expression in the SCN than a pulse presented towards the end of the dark period (ZT21). Light-induced Fos expression is attenuated by a vasopressin V1a antagonist. B, Data (median numbers of Fos cells counted per SCN section) from all individual animals are given as points (mean difference 0.39, 95% CI 0.1 to 0.68, **P=0.0095). C, Data (median numbers of Fos cells counted per SCN section) from all individual animals are given as points (mean difference 0.54, 95% CI -1.1 to 0.02, **P=0.029). D, Light stimulation increases the vasopressin content in SCN microdialysates in the ‘early morning’ group (light exposure at ZT3) but not the ‘evening’ group (light at ZT12) as measured by radioimmunoassay (RM ANOVA followed by Bonferroni’s and Tukey’s multiple comparisons tests). Mean difference 0.54, 95% CI 0.23 to 0.85, ***P=0.0001; mean difference 0.41, 95% CI 0.1 to 0.72, **P=0.005; mean difference -0.47, 95% CI -0.75 to -0.18, +++P=0.0006. Bars show means+S.E.M. Numbers in columns are n per group.

Figure 7B source data.xlsx; Figure 7C source data.xlsx; Figure 7D source data.xlsx

Table 1. Primary Antibodies used for retina and SCN immunohistochemistry
Supplementary animation:

Animation of confocal images, showing cumulative stacking of sequential z slices from a retina flat mount, providing a 3D representation of the dendritic arborization of Venus filled (green) vasopressin expressing retinal ganglion cells.

References


oxytocin release from the dendrites of hypothalamic neurons while inhibiting oxytocin release from their terminals in the neurohypophysis. *J Neurosci* 23, 10351-10358.


A. Calbindin
B. Calretinin
C. Parvalbumin
D. Somatostatin
E. Vasoactive intestinal polypeptide
F. Tyrosine hydroxylase
G. Glutamic acid decarboxylase 65/67
H. Glycine
I. Choline acetyltransferase
J. Dopamine β-hydroxylase

Tsuji et al., Figure 2
Tsuji et al., Figure 5

A. GFP / FOS

B. Graph showing % c-Fos positive VP-RGCs over time.

C. Voltage clamp and current clamp recordings.

D. Additional voltage clamp recordings.

E. Enlarged image of GFP expression.

F. Voltage change over time.

G. Bar graph comparing Vm (mV) in different conditions.
Tsuji et al., Figure 6
Tsuji et al., Figure 7

A. No Light, Light, Light + Antag

B. Log of median c-Fos cells/SCN section for Light ZT15 and Light ZT21, showing significant differences.

C. Log of median c-Fos cells/SCN section for Light Veh and Light+Antag ZT21, with Light+Antag showing lower values.

D. Vasopressin (normalized to first sample) for Sample 2 to 5, showing Light stimulation and significant differences at ZT3 and ZT12.
Table:

**T1:** Primary antibodies used for retina and SCN immunohistochemistry

<table>
<thead>
<tr>
<th>PRIMARY ANTIBODIES</th>
<th>CODE</th>
<th>SUPPLIER</th>
<th>DILUTION</th>
<th>HOST</th>
</tr>
</thead>
<tbody>
<tr>
<td>eGFP</td>
<td>AB3080</td>
<td>Millipore, UK</td>
<td>1:1000</td>
<td>rabbit</td>
</tr>
<tr>
<td>eGFP</td>
<td>MAB3580</td>
<td>Millipore, UK</td>
<td>1:1000</td>
<td>mouse</td>
</tr>
<tr>
<td>Venus (GFP &amp; YFP)</td>
<td>ab13797</td>
<td>Abcam, UK</td>
<td>1:15000</td>
<td>chicken</td>
</tr>
<tr>
<td>tdTomato</td>
<td>362496</td>
<td>Clontech</td>
<td>1:500</td>
<td>rabbit</td>
</tr>
<tr>
<td>Gastrin Releasing Peptide</td>
<td>ab43834</td>
<td>Abcam, UK</td>
<td>1:500</td>
<td>rabbit</td>
</tr>
<tr>
<td>Vasoactive Intestinal Peptide</td>
<td>20077</td>
<td>Immunostar, Newmarket Scientific, UK</td>
<td>1:500</td>
<td>rabbit</td>
</tr>
<tr>
<td>Melanopsin</td>
<td>AB19306</td>
<td>Abcam, UK</td>
<td>1:100</td>
<td>rabbit</td>
</tr>
<tr>
<td>Neuropeptide Y</td>
<td>22940</td>
<td>Immunostar, Newmarket Scientific, UK</td>
<td>1:500</td>
<td>rabbit</td>
</tr>
<tr>
<td>Somatostatin</td>
<td>20067</td>
<td>Immunostar, Newmarket Scientific, UK</td>
<td>1:500</td>
<td>rabbit</td>
</tr>
<tr>
<td>Vasopressin</td>
<td>PS41</td>
<td>Professor H Gainer (NIH, Bethesda, MD)</td>
<td>1:1000</td>
<td>mouse</td>
</tr>
<tr>
<td>Vasopressin</td>
<td>PC234L</td>
<td>Merck Chemicals Ltd, UK</td>
<td>1:200</td>
<td>rabbit</td>
</tr>
<tr>
<td>Calbindin D-28K</td>
<td>300</td>
<td>Swant, Switzerland</td>
<td>1:500</td>
<td>mouse</td>
</tr>
<tr>
<td>Calretinin</td>
<td>7699/3H</td>
<td>Swant, Switzerland</td>
<td>1:500</td>
<td>rabbit</td>
</tr>
<tr>
<td>Parvalbumin</td>
<td>24428</td>
<td>Immunostar, Newmarket Scientific, UK</td>
<td>1:500</td>
<td>rabbit</td>
</tr>
<tr>
<td>Glutamate Decarboxylase 65/67</td>
<td>ADI-MSA-225</td>
<td>Enzo Life Sciences (UK) LTD, Exeter, UK</td>
<td>1:1000</td>
<td>mouse</td>
</tr>
<tr>
<td>Vesicular Glutamate Transporter 2</td>
<td>135404</td>
<td>Synaptic Systems, Germany</td>
<td>1:1000</td>
<td>guinea pig</td>
</tr>
<tr>
<td>Glycine</td>
<td>AB5020</td>
<td>Millipore, UK</td>
<td>1:100</td>
<td>rabbit</td>
</tr>
<tr>
<td>Tyrosine Hydroxylase</td>
<td>AB152</td>
<td>Millipore, UK</td>
<td>1:1000</td>
<td>rabbit</td>
</tr>
<tr>
<td>Dopamine Beta Hydroxylase</td>
<td>AB1585</td>
<td>Millipore, UK</td>
<td>1:2000</td>
<td>rabbit</td>
</tr>
<tr>
<td>Choline Acetyltransferase</td>
<td>AB144P</td>
<td>Millipore, UK</td>
<td>1:1000</td>
<td>goat</td>
</tr>
<tr>
<td>Fos</td>
<td>PC38</td>
<td>Millipore, UK</td>
<td>1:20000</td>
<td>rabbit</td>
</tr>
<tr>
<td>Fos</td>
<td>226003</td>
<td>Synaptic Systems, Germany</td>
<td>1:100000</td>
<td>rabbit</td>
</tr>
</tbody>
</table>

**T2:** Secondary antibodies and visualization reagents used for retina and SCN immunohistochemistry

<table>
<thead>
<tr>
<th>SECONDARY ANTIBODIES:</th>
<th>CODE</th>
<th>SUPPLIER</th>
<th>DILUTION</th>
<th>Host</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biotin-anti-rabbit IgG</td>
<td>BA-1100</td>
<td>Vector Laboratories Ltd, UK</td>
<td>1:500</td>
<td>horse</td>
</tr>
<tr>
<td>Biotin-anti-mouse IgG</td>
<td>BA-2001</td>
<td>Vector Laboratories Ltd, UK</td>
<td>1:500</td>
<td>horse</td>
</tr>
<tr>
<td>Biotin-anti-guinea pig IgG</td>
<td>BA-7000</td>
<td>Vector Laboratories Ltd, UK</td>
<td>1:500</td>
<td>goat</td>
</tr>
<tr>
<td>Biotin-anti-rabbit IgG</td>
<td>BA-1000</td>
<td>Vector Laboratories Ltd, UK</td>
<td>1:500</td>
<td>goat</td>
</tr>
<tr>
<td>Biotin-anti-mouse IgG</td>
<td>BA-9200</td>
<td>Vector Laboratories Ltd, UK</td>
<td>1:500</td>
<td>goat</td>
</tr>
<tr>
<td>Alexa 488 anti-chicken</td>
<td>A11039</td>
<td>Life Technologies, UK</td>
<td>1:500</td>
<td>goat</td>
</tr>
<tr>
<td>Biotin-Anti-Chicken IgY</td>
<td>703-066-155</td>
<td>Stratech Scientific Ltd, UK</td>
<td>1:500</td>
<td>donkey</td>
</tr>
</tbody>
</table>

VISUALISED WITH:

| Streptavidin, Alexa Fluor 488 conjugate      | S-11223 | Life Technologies, UK       | 1:500    |
| Streptavidin, Alexa Fluor 555 conjugate      | S-21381 | Life Technologies, UK       | 1:500    |
| Streptavidin, Alexa Fluor 647 conjugate      | S-21374 | Life Technologies, UK       | 1:500    |